Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Zuellig Pharma

Sosei Heptares Eyes Asia Build-Out On Internal, External Assets

Japan-UK firm is looking to build on a combination of internal and external assets to pursue a more independent business development path in Japan and beyond, in parallel with ongoing discovery and development collaborations.

Asia Pacific Japan

Asia Deal Watch: Qpex Partners Its Experimental Antibiotics With Brii In Greater China

Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.

Deals Asia Pacific

Interview: DKSH Building Healthcare Services In Changing Asian Markets

Market expansion services provider has its headquarters in Switzerland but a long history and most of its business in Southeast Asia, where the global head of its Business Unit Healthcare tells Scrip it continues to build a broad range of services based around knowledge and penetration of local markets.

Asia Pacific Business Strategies

Boryung Expands In Asia Through Zuellig Deal

Boryung Pharm's original antihypertensive drug continues to increase its global presence, this time through the biggest license agreement so far for the product, with Zuellig Pharma, which will enable the South Korean pharma to sell fimasartan in the rapidly growing Southeast Asian markets.

BioPharmaceutical Asia Pacific
See All

Company Information

  • Industry
  • Services
UsernamePublicRestriction

Register